{
    "clinical_study": {
        "@rank": "153069", 
        "arm_group": [
            {
                "arm_group_label": "Pioglitazone group", 
                "arm_group_type": "Experimental", 
                "description": "Pioglitazone 15 mg/day will be given in this group for 9 months"
            }, 
            {
                "arm_group_label": "Metformin group", 
                "arm_group_type": "Active Comparator", 
                "description": "Metformin 0.85 twice daily will be given in this group for 9 months as control."
            }
        ], 
        "brief_summary": {
            "textblock": "Cardiovascular complications account for the highest mortality in type 2 diabetic patients,\n      mainly due to ischeamia heart disease (IHD). Most of the attention in treating IHD in type 2\n      diabetes is understandably directed toward treating coronary artery conditions. However\n      there are other treatable culprits in these patients.\n\n      Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with IHD, even\n      in the absence of hypertension. It is a strong predictor of cardiovascular events and\n      all-cause mortality. In one study, the presence of LVH was a stronger predictor of mortality\n      than either multivessel coronary disease or impaired left ventricular function. Regression\n      of LVH has been associated with an improved prognosis, independent of change in blood\n      pressure (BP). Therefore, cardiovascular events and mortality in type 2 diabetes with IHD\n      might will be reduced if we can find novel therapies to regress LVH.\n\n      Pioglitazone can improve atherosclerosis. Therefore, we hypothesied that pioglitazone can\n      regress the left ventricular mass (LVM) in type 2 diabetes with IHD.Therefore, in this\n      study, we will treat patients with pioglitazone, and we will also metformin as control."
        }, 
        "brief_title": "Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "LVM", 
            "Type 2 Diabetic Patients With IHD", 
            "Endothelial Function"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus, Type 2", 
                "Heart Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  type 2 diabetes\n\n          -  aged 40\uff5e75 years old\n\n          -  with IHD\n\n        Exclusion Criteria:\n\n          -  heart failure\n\n          -  renal failure\n\n          -  hypertension (>130/80 mmHg)\n\n          -  hemoglobin A1c 9%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947790", 
            "org_study_id": "2013Wze051"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pioglitazone group", 
                "intervention_name": "pioglitazone group", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Metformin group", 
                "intervention_name": "Metformin group", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pioglitazone", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 2 diabetes", 
            "left ventricular mass", 
            "pioglitazone"
        ], 
        "lastchanged_date": "September 20, 2013", 
        "location": [
            {
                "contact": {
                    "email": "xianglin832010@hotmail.com", 
                    "last_name": "Xiang Lin, MD", 
                    "phone": "+8602768879059"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430070"
                    }, 
                    "name": "Xiang Guangda"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Guangda64@hotmail.com", 
                    "last_name": "Xiang Guangda, MD, Ph D", 
                    "phone": "+862768878410"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuhan City", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "43000"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease", 
        "overall_contact": {
            "email": "Guangda64@hotmail.com", 
            "last_name": "Xiang Guangda, MD", 
            "phone": "+8602768878410"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The changes of LVM", 
            "safety_issue": "Yes", 
            "time_frame": "The LVM will be measured at baseline, 6 momth and 9 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947790"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wuhan General Hospital of Guangzhou Military Command", 
            "investigator_full_name": "Xiang Guang-da", 
            "investigator_title": "Pioglitazone regress the left ventricular mass in normotensive type 2 diabetic patients with ischeamia heart disease", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The changes of endothelial function", 
            "safety_issue": "Yes", 
            "time_frame": "The endothelial function will be measured at baseline, 6 month and 9 month"
        }, 
        "source": "Wuhan General Hospital of Guangzhou Military Command", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xiang Guang-da", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}